22300-52-3

Basic information

• Product Name: 4,5-Dibromo-2H-1,2,3-triazole
• Synonyms: 2H-1,2,3-Triazole, 4,5-dibromo-
• CAS NO: 22300-52-3
• Molecular Formula: C₂HBr₂N₃
• Molecular Weight: 226.86
• EINECS: 200-110-4
• Mol File: 22300-52-3.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 347.5±22.0 °C(Predicted)
• Appearance: /
• Density: 2.620
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 5.22±0.70(Predicted)
• CAS DataBase Reference: 4,5-Dibromo-2H-1,2,3-triazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-Dibromo-2H-1,2,3-triazole(22300-52-3)
• EPA Substance Registry System: 4,5-Dibromo-2H-1,2,3-triazole(22300-52-3)

Safety Data

• Hazardous Substances Data: 22300-52-3(Hazardous Substances Data)

Usage

Uses

4,5-Dibromo-2H-triazole was a useful reagent in discovery of selective small molecular inhibitors of monoacylglycerol acyltransferase 3.

Upstream product

• 288-36-8 1 ,2,3-Triazole 
• 288-36-8 1,2,3-triazole 

Downstream Products

• 1248676-21-2 4,5-dibromo-2-ethyl-2H-1,2,3-triazole 
• 1248676-59-6 1-ethyl-4,5-dibromo-1H-1,2,3-triazole 
• 28938-17-2 2-methyl-4,5-dibromo-2H-1,2,3-triazole 
• 25537-64-8 1-methyl-4,5-dibromo-1H-1,2,3-triazole 
• 1192847-33-8 4,5-dibromo-2-(2-nitrophenyl)-2H-1,2,3-triazole 
• 1192847-37-2 C₈H₃Br₃N₄O₂ 
• 1192847-32-7 C₉H₄Br₂N₄ 
• 1192847-35-0 C₉H₄Br₂N₄O₃ 
• 1192847-34-9 C₈H₃Br₂FN₄O₂ 
• 1192847-36-1 C₁₁H₆Br₂F₃N₃O₂ 

Relevant articles and documents

TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF

The present disclosure relates generally to compounds of Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).

LPA RECEPTOR ANTAGONISTS AND USES THEREOF

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

STEROID DERIVATIVE REGULATORS, METHOD FOR PREPARING THE SAME, AND USES THEREOF

The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound as shown in formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator of GABA A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases, wherein the substituents of the formula (I) are as defined in the description.